^
Association details:
| Biomarker: | BCR-ABL1 P465S |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Published date:
08/05/2022
Excerpt:
Chronic Myeloid Leukemia…The table below lists the BCR::ABL1 kinase domain mutations that should NOT be treated with asciminib…A337T or P465S
